一、审议通过《关于拟出售全资子公司 100%股权暨关联交易的议案》 第八届监事会第十一次会议决议公告 证券代码：002172 证券简称：澳洋健康 公告编号：2023-44 江苏澳洋健康产业股份有限公司 第八届监事会第十一次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确、完整，没有虚假记 载、误导性陈述或者重大遗漏。 江苏澳洋健康产业股份有限公司（以下简称"本公司"或"公司"）第八届监事 会第十一次会议于 2023 年 10 月 13 日以通讯方式发出会议通知，于 2023 年 10 月 23 日下午在公司会议室以现场会议方式召开。会议应出席监事 3 名，实际出 席会议监事 3 名。会议由公司监事会主席顾慎侃先生主持，符合《公司法》及公 司《章程》的有关规定。会议经认真审议，通过如下议案： 1 监事会认为：公司本次计划出售全资子公司江苏澳洋材料科技有限公司100% 股权事项遵循了公开、公平、公正的原则，交易价格公允，符合公司的经营发展 需要及全体股东的利益，不会对公司独立性构成影响，不会侵害中小股东利益， 符合中国证券监督管理委员会和深圳证券交易所的有关规定。 表决结果：同意 3 票，反对 0 票 ...

独立董事关于公司第八届董事会第十四次会议相关事项的独立意见 江苏澳洋健康产业股份有限公司 独立董事关于公司第八届董事会 第十四次会议相关事项的独立意见 根据《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管指 引第1号——主板上市公司规范运作》、公司《独立董事工作制度》等相关规定， 作为公司的独立董事，我们本着实事求是的态度，依据客观公正的原则，我们认真 阅读了公司提供的相关资料，并听取公司关于本次会议事项的相关说明后，基于个人 独立判断，对公司第八届董事会第十四次会议相关事项发表独立意见如下： （3）本次交易构成关联交易。公司董事会在审议相关议案时，关联董事进行 了回避，没有参加议案表决，也没有代其他董事行使表决权，关联交易决策及表决 程序符合《深圳证券交易所股票上市规则》、《公司章程》的有关规定，不存在损 害公司及其他股东利益的行为。 （4）本次交易标的的交易价格是公司与澳洋集团按照目标公司经审计评估后 的价格协商确定的，不会损害公司及其股东、特别是中小股东利益。 因此我们同意《关于拟出售全资子公司 100%股权暨关联交易的议案》，并同意 将上述议案提交公司股东大会审议。 江苏澳洋健康产业股份 ...

Financial Performance - The company's operating revenue for the first half of 2023 was CNY 1,063,775,243.53, representing a 2.73% increase compared to CNY 1,035,464,171.95 in the same period last year[19]. - The net profit attributable to shareholders decreased by 22.95% to CNY 35,465,167.67 from CNY 46,026,810.22 year-on-year[19]. - The net profit after deducting non-recurring gains and losses fell by 32.70% to CNY 29,966,025.20 compared to CNY 44,528,379.77 in the previous year[19]. - The operating profit increased by 65.16% to ¥70,772,983.56, driven by increased gains from the disposal of subsidiaries and reduced interest expenses[36]. - The total profit for the first half of 2023 was 49,882,491.08 CNY, down from 54,464,907.13 CNY in the previous year, reflecting a decline of approximately 8.7%[127]. - The total comprehensive income for the first half of 2023 was 35,836,310.83 CNY, down from 46,447,388.03 CNY in the same period of 2022[128]. Cash Flow and Liquidity - The net cash flow from operating activities improved significantly, reaching CNY 139,430,871.19, a 169.35% increase from a negative cash flow of CNY 201,049,793.10 in the same period last year[19]. - The cash and cash equivalents at the end of the period decreased by 102.49% to a net increase of -¥3,996,261.71, compared to a significant increase of ¥160,276,308.56 in the previous year[36]. - The net cash flow from operating activities for the first half of 2023 was ¥139,430,871.19, a significant improvement compared to a net outflow of ¥201,049,793.10 in the same period of 2022[132]. - The ending balance of cash and cash equivalents decreased to ¥350,919,280.95 at the end of the first half of 2023, down from ¥292,734,363.88 at the end of the first half of 2022[134]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 2,536,771,642.07, down 6.32% from CNY 2,708,031,538.51 at the end of the previous year[19]. - The total liabilities decreased to CNY 2,474,796,043.49 from CNY 2,681,138,250.76, a reduction of about 7.7%[121]. - The total current assets decreased from 1,808,681,669.58 CNY to 1,639,657,888.39 CNY, a reduction of approximately 9.3%[119]. - The total equity attributable to the parent company increased by 80.12% to ¥79,728,277.82, reflecting improved profitability[37]. Investment and Development - Research and development investment rose to ¥1,147,695.46, marking a 100% increase from zero in the previous year, indicating a commitment to innovation[36]. - The company plans to build a new orthopedic secondary specialty hospital with a total of 300 beds and a construction area of 28,000 square meters, funded through a private placement[32]. - The company is actively pursuing investment opportunities in the healthcare sector to enhance its brand and service capabilities in East China[30]. - Future outlook includes continued investment in new product development and market expansion initiatives[79]. Market and Pricing Strategy - The company is focusing on expanding its market presence in the healthcare sector through strategic pricing adjustments[79]. - The overall sales performance indicates a stable growth trajectory in the healthcare and pharmaceutical segments[79]. - The company is actively monitoring market prices to optimize procurement strategies and enhance profitability[79]. Risks and Challenges - The report highlights risks related to national policies affecting the healthcare industry, urging investors to remain cautious[4]. - The company faces macroeconomic risks that could impact consumer demand and purchasing power, particularly in the context of a slowing economy[57]. - Regulatory changes in the healthcare sector pose risks to the company's operations, particularly due to policies affecting the pharmaceutical logistics business[57]. Shareholder and Equity Information - The company plans not to distribute cash dividends or issue bonus shares for this reporting period[5]. - The total number of shares was 765,732,360, with 100% ownership[104]. - The largest shareholder, Aoyang Group Co., Ltd., holds 30.74% of the shares, totaling 235,349,599 shares, with 90,300,000 shares pledged[105]. Social Responsibility and Community Engagement - The company actively engages in social responsibility initiatives, including free medical consultations in rural areas, which have received positive feedback from the community[68]. Accounting and Financial Reporting - The financial report for the first half of 2023 has not been audited[117]. - The company’s financial statements comply with the accounting standards set by the Ministry of Finance, reflecting its financial position as of June 30, 2023[175].

非经营性资金占用及其他关联资金往来情况汇总表 单位：万元 江苏澳洋健康产业股份有限公司 2023 年半年度 | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公司的 | 上市公司核算的 | 2023 年期初占 | 2023 年半年度 占用累计发生金 | 2023 年半年 度占用资金的 | 2023 年半年度 2023 偿还累计发生金 | 年 6 月占用 | 占用形成原因 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 关联关系 | 会计科目 | 用资金余额 | 额（不含利息） | 利息(如有) | 额 | 资金余额 | | | | | | | | | | | | | | 非经营性占用 | | 控股股东、实际控 制人及其附属企业 | | | | | | | | | | | | | | | | | | | | | | 非经营性占用 | | 小计 | - | - | - | | | | | | - | - | | 前控股股东、实际 | | | | | | | | | | 非经营性占用 | | ...

江苏澳洋健康产业股份有限公司独立董事 关于控股股东及其他关联方占用公司资金、公司对外担保情况 的专项说明和独立意见 根据《上市公司独立董事规则》、《深圳证券交易所上市公司自律监管指引第 1号——主板上市公司规范运作》及《公司章程》等有关规定，作为公司的独立董 事，我们本着实事求是的态度，依据客观公正的原则，对公司截至2023年6月30日的 控股股东及其他关联方占用公司资金情况、公司对外担保情况、募集资金使用情况 等进行了核查，核查情况如下： 根据中国证监会《上市公司监管指引第8 号——上市公司资金往来、对外担保 的监管要求》及《深圳证券交易所股票上市规则》《公司章程》的有关规定，作为 公司独立董事，我们本着对公司、全体股东负责的态度，我们对控股股东及其他关 联方占用公司资金、公司对外担保情况进行了认真的核查，认为公司严格执行国家 的有关法律法规，加强资金管理、对外担保管理，严格控制资金往来及对外担保风 险。公司与控股股东及关联方的资金往来属于正常的经营性资金往来，控股股东及 关联方不存在非经营性占用公司资金的情形。现发表独立意见如下： 1、截至2023年6月30日，公司与控股股东及其子公司、其他关联方不存在关 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥543,869,982.70, a decrease of 15.49% compared to ¥643,577,490.50 in the same period last year[3] - Net profit attributable to shareholders was ¥36,326,684.73, representing an increase of 11.78% from ¥32,498,869.97 year-on-year[3] - The net profit after deducting non-recurring gains and losses was ¥11,677,474.17, down 70.62% from ¥39,746,660.40 in the previous year[3] - Basic and diluted earnings per share increased by 25.00% to ¥0.05 from ¥0.04 year-on-year[3] - Total operating revenue for Q1 2023 was CNY 543.87 million, a decrease of 15.5% compared to CNY 643.58 million in Q1 2022[15] - Net profit for Q1 2023 reached CNY 36.66 million, an increase of 11.4% from CNY 32.79 million in Q1 2022[16] - The company's total assets decreased to CNY 2.55 billion in Q1 2023 from CNY 2.71 billion in Q1 2022, a decline of 5.8%[12] - The company's equity attributable to shareholders increased to CNY 80.59 million in Q1 2023 from CNY 44.26 million in Q1 2022, a growth of 82%[13] Cash Flow and Liquidity - The net cash flow from operating activities improved by 62.46%, reaching -¥121,279,156.93 compared to -¥323,103,011.47 in the same period last year[3] - The net cash flow from financing activities decreased by 95.20% compared to the previous year, attributed to no inter-company borrowing repayments during the period[8] - The net increase in cash and cash equivalents decreased by 227.27% year-on-year, primarily due to a significant increase in cash from the disposal of long-term assets in the previous period[8] - The cash and cash equivalents at the end of the reporting period were 722,967,577.03 yuan, down from 984,155,292.34 yuan at the beginning of the year[11] - The company’s cash and cash equivalents decreased to CNY 744.11 million in Q1 2023 from CNY 755.60 million in Q1 2022[12] - Total cash inflow from financing activities was 551,934,820.35 CNY, while cash outflow was 567,103,261.31 CNY, resulting in a net cash flow of -15,168,440.96 CNY[19] - Cash received from sales of goods and services was 496,348,199.74 CNY, a decrease from 533,277,746.93 CNY year-over-year[18] Investment and Assets - Investment income for the period was ¥25,827,820.99, a significant increase from a loss of ¥142,691.76 in the same period last year[6] - The company recognized a non-recurring gain of 25,827,820.99 yuan from the sale of its wholly-owned subsidiary, Jiangsu Aoyang New Materials Technology Co., Ltd.[9] - The total current assets at the end of the reporting period amounted to 1,651,777,974.50 yuan, down from 1,808,681,669.58 yuan at the beginning of the year[11] - The balance of accounts receivable increased to 394,589,122.04 yuan from 314,453,133.56 yuan at the beginning of the year[11] - The company reported a total cash inflow from operating activities of 680,114,077.87 CNY, down from 750,511,190.57 CNY in the previous period[18] - The company’s cash flow from investment activities showed a net outflow of -19,806,545.73 CNY, contrasting with a net inflow of 761,728,828.43 CNY in the previous period[19] Shareholder Information - The total number of common shareholders at the end of the reporting period is 63,763[8] - The largest shareholder, Aoyang Group Co., Ltd., holds 30.74% of shares, amounting to 235,349,599 shares, with 116,686,547 shares pledged[8] Costs and Expenses - Total operating costs for Q1 2023 were CNY 524.02 million, down 19.6% from CNY 651.94 million in the same period last year[15] - The company experienced a 71.62% reduction in financial expenses due to a decrease in total borrowings and corresponding interest expenses[6] - Cash used for debt repayment decreased by 60.12% compared to the same period last year, primarily due to a reduction in loan repayment amounts[8] - Cash paid for dividends and interest increased by 67.88% year-on-year, mainly due to an increase in dividends paid to minority shareholders[8] - The company paid 551,296,828.73 CNY for purchasing goods and services, down from 845,188,472.01 CNY in the previous period[18] - The cash outflow for other investment activities was 25,987,067.34 CNY, compared to 189,074,637.19 CNY in the previous period[19]

Business Transformation - The company reported a significant shift in focus towards the healthcare sector after divesting its non-core business, with full commitment to medical health operations as of May 7, 2022[18]. - The company has undergone a transformation from primarily producing viscose staple fiber to establishing a dual business model in chemical fibers and health industries since 2015[17]. - The company completed the asset transfer and announced the completion of the transaction on May 7, 2022, marking a full transition to the health industry[93]. - The company divested from its chemical fiber business to focus entirely on the healthcare sector, aligning with its strategic transformation[88]. Financial Performance - The company's operating revenue for 2022 was ¥2,021,311,317.17, a decrease of 33.27% compared to ¥3,028,918,811.03 in 2021[20]. - The net profit attributable to shareholders was -¥15,389,790.15 in 2022, showing an improvement of 98.52% from -¥1,038,913,881.13 in 2021[20]. - The total assets at the end of 2022 were ¥2,708,031,538.51, down 29.17% from ¥3,823,219,194.07 at the end of 2021[20]. - The company reported a basic and diluted earnings per share of -¥0.02 in 2022, an improvement of 98.51% from -¥1.34 in 2021[20]. - The company reported a loss of ¥22,202,585.29 from investment income, representing 2,302.57% of total profit[65]. Revenue Breakdown - Revenue from medical services increased by 6.18% to CNY 1,006,694,205.21, accounting for 49.80% of total revenue[51]. - Revenue from pharmaceutical logistics decreased by 2.88% to CNY 997,697,746.78, representing 49.36% of total revenue[51]. - The total revenue for Jiangsu Aoyang Health Industry Co., Ltd. in 2022 was 613.84 million RMB, showing a significant increase compared to the previous year[105]. - The company reported a total revenue of 688.6 million with a growth rate of 64.88% compared to the previous year[152]. Strategic Initiatives - The company aims to enhance its brand and expand specialty services, focusing on building a high-level research institute in oncology[47]. - The company is actively pursuing investment opportunities in the medical service industry to strengthen its competitive position in East China[47]. - The company aims to optimize assets and upgrade the health industry and brand, focusing on the integration of medical, health, and elderly care services[94]. - The company is focusing on expanding its market presence in the health industry through strategic procurement[152]. Market Trends - The healthcare industry in China has shown a compound annual growth rate (CAGR) of 10.58% in total health expenditure from 2012 to 2021, reaching ¥76,844.99 billion[32]. - The number of private hospitals in China increased from 9,786 in 2012 to 24,766 in 2021, representing a compound annual growth rate of 9.73%[38]. - The total number of hospitals in China grew from 23,170 in 2012 to 36,570 in 2021, with the proportion of private hospitals rising from 42.24% to 67.72%[38]. Governance and Compliance - The company’s financial report is guaranteed to be true, accurate, and complete by its board of directors and management, ensuring accountability[3]. - The company has engaged Lixin Certified Public Accountants for auditing, ensuring compliance and transparency in financial reporting[19]. - The company has maintained a stable governance structure, complying with relevant laws and regulations without any major issues[135]. Employee and Management Information - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 3.64 million[116]. - The total number of employees at the end of the reporting period was 2,274, with 1,499 being technical personnel, representing approximately 66% of the workforce[124]. - The company conducted various training programs throughout the year, covering management, chemical fiber professional skills, and medical professional skills[127]. Future Outlook - The company plans to expand its market presence by entering three new provinces in 2023, aiming for a 25% increase in market share[108]. - The company has set a performance guidance for 2023, targeting a revenue growth of 30% compared to 2022[108]. - Future guidance includes an expected EBITDA margin improvement of 3% as a result of strategic investments and operational efficiencies[154]. Legal Matters - The company is involved in a lawsuit with a claim amount of ¥4,011.05 million, which has been recognized as a liability[147]. - Another lawsuit involves a claim amount of ¥2,616.29 million, with the court proceedings already initiated[147]. - The company has settled a dispute involving a claim of ¥1,682.42 million, with the execution of the settlement completed[148]. Risk Management - The company has acknowledged potential risks related to national policies affecting the healthcare industry, urging investors to remain aware of investment risks[3]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[138]. - The company has not encountered any bankruptcy reorganization matters during the reporting period[146].

江苏澳洋健康产业股份有限公司 关于举行 2022 年年度报告业绩说明会的通知 本公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚 假记载、误导性陈述或者重大遗漏负连带责任。 江苏澳洋健康产业股份有限公司《2022 年年度报告》全文及摘要已于 2023 年 3 月 23 日经公司第八届董事会第十次会议审议通过。《2022 年年度报告》全 文及摘要已于 2023 年 3 月 24 日刊登于巨潮资讯网站（http://www.cninfo.com.cn） 上，《2022 年年度报告摘要》同时刊登在《证券时报》上，供全体股东和投资者 查询。 为使广大投资者进一步详细了解公司年报信息，公司定于 2023 年 4 月 7 日 （星期五）15:00-17:00 在深圳证券信息有限公司提供的网上平台举行年度报告 说明会，本次年度报告说明会将采用网络远程的方式举行，投资者可登录"全景 •路演天下"（http://rs.p5w.net）参与公司年度报告说明会。 关于举行 2022 年年度报告业绩说明会的通知 证券代码：002172 证券简称：澳洋健康 公告编号：2023-18 届时公司董事长兼总经理沈学如先生，董事 ...

Group 1: Viscose Staple Fiber Business - The market consensus is optimistic about the rising price trend of viscose, and the company is confident in the development of its viscose staple fiber business [2] - The Xinjiang production base is accelerating environmental investments and acceptance, aiming for early resumption of production while phasing out outdated capacity and expanding downstream appropriately [2] Group 2: Health Industry Development - In the medical service sector, the company has established a healthcare system centered around Aoyang Hospital, with branches like Yangshe, Sanxing, and Shunkang, focusing on basic medical care and specialty services [3] - Aoyang Pharmaceutical has become one of the largest private pharmaceutical logistics companies in East China, with a modern distribution network covering the region and extending nationwide [3] - The company aims to leverage its public platform for both internal development and external expansion in the health industry, striving to strengthen its position in this emerging main business [3]

证券代码：002172 证券简称：澳洋科技 江苏澳洋科技股份有限公司投资者关系活动记录表 编号：2015-01 | --- | --- | --- | |----------------|--------------------------------|------------------------------------------------------------| | | | | | | | 特定对象调研 □分析师会议 | | 投资者关系活动 | □ | 媒体采访 □业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 通金投资 陈坤、国信证券 苏淼、华安基金 袁银泉、中国人寿资 | | 人员姓名 | | 管 赵文龙、国海富兰克林基金 张琼钢、兴业证券 郑方镳 李鸣 | | | | 孙佳丽、细水投资 刘伟、鸿道投资 应振洲、农银汇理基金 徐治 | | | | 彪 陈继业、华安基金 周阳、中银基金 王帅、东吴人寿 张亚辉、 | | | | 汇添富基金 李华伟、东方资管 周云 蔡志鹏 ...